Ndonovo Therapeutics Inc (ENDV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 6,925 | 8,528 | 9,294 | 7,231 | -18,475 |
| Depreciation Amortization | 688 | 497 | 338 | 166 | 758 |
| Accounts receivable | N/A | N/A | N/A | -3 | N/A |
| Other Working Capital | 1,708 | 1,251 | 956 | 456 | 2,009 |
| Other Operating Activity | -9,199 | -10,680 | -10,928 | -8,022 | 15,029 |
| Operating Cash Flow | $122 | $-404 | $-339 | $-173 | $-679 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | -121 | 195 | 146 | N/A | 465 |
| Debt Repayment | N/A | -40 | -20 | -20 | N/A |
| Common Stock Issued | 11 | 257 | 253 | 207 | 142 |
| Other Financing Activity | -10 | -8 | -8 | -3 | -14 |
| Financing Cash Flow | $-120 | $404 | $372 | $184 | $593 |
| Beginning Cash Position | 0 | 0 | 0 | 0 | 86 |
| End Cash Position | 2 | 0 | 33 | 11 | 0 |
| Net Cash Flow | $2 | $0 | $33 | $11 | $-86 |
| Free Cash Flow | |||||
| Operating Cash Flow | 122 | -404 | -339 | -173 | -679 |
| Free Cash Flow | 122 | -404 | -339 | -173 | -679 |